A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the existing as well as new players in this market in designing their business strategies.According to the research study, in 2013, the global dilated cardiomyopathy therapeutics market was valued at US$651 mn and is anticipated to decline to US$328.6 mn by the end of 2020. This market is projected to exhibit -7% CAGR between 2014 and 2020.
Request For Report Brochure For Industry Insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2293
The growing prevalence of congestive heart failure is the only key factor that is driving the demand for dilated cardiomyopathy therapeutics; however, there are many factors that are expected to hamper the growth of this market in the forecast period. Easy availability of pacemakers, implantable cardioverter defibrillators, promising developments in gene therapy, and implantable devices such as heart pumps are the factors curbing the growth of the dilated cardiomyopathy therapeutics market. In addition, the various side effects associated with the use of dilated cardiomyopathy therapeutics and other easier therapies using devices that have negligible side effects will hold back the growth of this market in the next few years.
On the basis of drug class, the global market for dilated cardiomyopathy therapeutics has been classified into aldosterone antagonists, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. By pipeline drugs, the market has been segmented into ARRY-797, CAP-1002, MYDICAR, ixCELL-DCM, and OR-1. A detailed analysis of these segments has been presented in the research report.
The global dilated cardiomyopathy therapeutics market has been divided on the basis of geography into Europe, North America, Asia Pacific, and Rest of the World. In 2013, North America accounted for the largest share of the market owing to the growing adoption of branded drugs, and the rising occurrence of congestive heart failure. In the U.S., dilated cardiomyopathy strikes around five to eight people amongst every 100,000. Asia Pacific and the Rest of the World markets for dilated cardiomyopathy therapeutics are growing at a fast pace owing to the increasing per capita income, improving economic standards, and rising demand for generic drugs.
Furthermore, the research report covers the competitive landscape of the global dilated cardiomyopathy therapeutics market including an overview of leading companies, their product portfolio, financial overview, business strategies, recent developments, and SWOT analysis. Some of the prominent players operating in the global market for dilated cardiomyopathy therapeutics are Novartis International AG, Celladon Corporation, Sanofi S.A., Vericel Corporation, AstraZeneca plc, Pfizer, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Janssen Pharmaceuticals, Inc., and Array BioPharma, Inc.
Browse Full Report: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html